Johnson and Johnson Options Activity Surges as Immunology and Neuroscience Units Emerge as Growth Engines

Johnson and Johnson drew notable attention in options markets on Tuesday, with 42,583 contracts trading across its shares, representing approximately 4.3 million underlying shares, among the most active in the S&P 500 that session. New November 20th expiration options also became available, with 94 days until expiry offering investors fresh positioning opportunities. On the business front, J&J's immunology and neuroscience divisions are emerging as key growth drivers, with new drug launches helping the company offset the revenue headwinds from Stelara losing patent exclusivity.

Analysts and income-focused investors continued to flag JNJ as a dependable dividend compounder, with 247wallst.com listing it among five blue-chip dividend stocks to buy in August, citing its track record of raising payouts and returning capital over decades.